Efficacy of vitamin e treatment for hand-foot syndrome in patients receiving capecitabine

Breast Care

Volumn 5, Issue 6, 2010, Pages 415-416

  Yamamoto, Daigo ^a,b   Yamamoto, Chizuko ^b   Iwase, Satoru ^c   Kuroda, Yujiro ^c   Odagiri, Hiroki ^d   Nagumo, Yoshinori ^e  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

^b Seiko Hospital   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^d HIROSAKI UNIVERSITY   (Japan)

^e Nagumo Clinic   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; CAPECITABINE; FLUOROURACIL;

BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DESQUAMATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDUCED DISEASE; HAND FOOT SYNDROME; HUMAN; LETTER; PAIN; PRIORITY JOURNAL; TREATMENT RESPONSE;

EID: 78650985854     PISSN: 16613791     EISSN: 16613805     Source Type: Journal    
DOI: 10.1159/000322660     Document Type: Letter

References (19)

1. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa T, Mori K, Shimma N, Umeda I, Ishitsuka H: Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. Eur J Cancer 1998;34:1274-81.
2. Fumoleau P, Largillier R, Clippe C: Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxanepretreated metastatic breast cancer. Eur J Cancer 2004;40:536-42.
3. Blum JL, Jones SE, Buzdar AU: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999;17:485-93.
4. Blum JL, Dieras V, Lo Russo PM: Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001a;92:1759-68.
5. Reichardt P, von Minckwitz G, Thuss-Patience PC: Multicenter phase II study of oral capecitabine (Xeloda()) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy. Ann Oncol 2003;14:1227-33.
6. Miller KD, Chap LI, Holmes FA, Cobleigh MA, Marcom PK, Fehrenbacher L, Dickler M, Overmoyer BA, Reimann JD, Sing AP, Langmuir V, Rugo HS: Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005;23:792-9.
7. Stockler MR, Sourjina T, Grimison P: A randomized trial of capecitabine (C) given intermittently (IC) rather than continuously (CC) compared to classical CMF as first-line chemotherapy for advanced breast cancer (ABC). J Clin Oncol 2007;25:1031.
8. Blum JL, Jones SE, Buzdar AU; on behalf of the Xeloda Breast Cancer Study Group: Capecitabine in 162 patients with paclitaxel-pretreated MBC: updated results and analysis of dose modification. Eur J Cancer 2001;37(suppl 6):190(abstr 693).
9. Leonard R, OShaughnessy J, Vukelja S: Detailed analysis of a randomized phase III trial: can the tolerability of capecitabine plus docetaxel be improved without compromising its survival advantage? Ann Oncol 2006;17:1379-85.
10. Frye DK: Capecitabine-based combination therapy for breast cancer: implications for nurses. Oncol Nurs Forum 2009;36:105-13.
11. Gressett SM, Stanford BL, Hardwicke F: Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract 2006;12:131-41.
12. LassereY, Hoff P: Management of hand-foot syndrome in patients treated with capecitabine (Xeloda). Eur J Oncol Nursing 2004;8:S31-40.
13. Kara IO, Sahin B, Erkisi M: Palmar-plantar erythrodysesthesia due to docetaxel-capecitabine therapy is treated with vitamin E without dose reduction. Breast 2006;15:414-24.
14. Yamamoto D, Iwase S, Kitamura K, Odagiri H, Yamamoto C, Nagumo Y: A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) Trial. Cancer Chemother Pharmacol 2008;61: 509-14.
15. Haller DG, Cassidy J, Clarke SJ: Potential regional differences for the tolerability profiles of fluoropyrimidines. J Clin Oncol 2008;2:2118-23.
16. Halliwell B, Gutteridge JMC: Free Radicals in Biology and Medicine. Oxford, Oxford University Press, 1993, pp. 188-276.
17. Lacouture ME, Wu S, Robert C: Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 2008;13:1001-11.
18. Asgari MM, Haggerty JG, McNiff JM: Expression and localization of thymidine phosphorylase/ platelet-derived endothelial cell growth factor in skin and cutaneous tumors. J Cutaneous Pathol 1999;26:287-94.
19. Milano G, Etienne-Grimaldi M-C, Mari M: Candidate mechanisms of capecitabine-related hand-foot syndrome. Br J Clin Pharmacol 2008;1-8.